Prevalence and Type Distribution of Human Papilloma Virus (HPV) in Oral, Oropharyngeal, Cervical, and Vulvovaginal Cancers

• Rahul G. Dholariya

  Department of Surgical Oncology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

• Ankur Tripathi

  Department of Surgical Oncology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

• Amritha Prabha Shankar

  Department of Surgical Oncology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

• M.S. Ganesh

  Department of Surgical Oncology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

• Ravoori Harish Babu

  Department of Surgical Oncology, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India

Background: Human papillomavirus (HPV) is a major etiological agent in cervical cancer and is increasingly recognized as a driver of other anogenital and head and neck squamous cell carcinomas (HNSCCs). The oncogenic potential of HPV is primarily mediated by high-risk genotypes such as HPV16, HPV18, HPV31, and HPV45, whose E6 and E7 oncoproteins disrupt p53 and retinoblastoma pathways. While the burden of HPV-associated cervical cancer is well documented, data on the prevalence and genotype distribution of HPV in oral, oropharyngeal, vulvar, and vaginal cancers in India remain limited.

Objective: To identify the disease burden and determine the prevalence and genotype distribution of high-risk HPV (16, 18, 31, 45) in biopsy-proven squamous cell carcinomas of the cervix, oral cavity, oropharynx, vulva, and vagina.

Methods: We conducted a retrospective analysis of 131 patients with squamous cell carcinomas diagnosed between September 2022 and August 2024 at Vydehi Institute of Medical Sciences and Research Centre, Bangalore, India. PCR-based HPV detection was employed to determine the presence of high-risk HPV types 16, 18, 31, and 45 targeting the E6/E7 regions of high-risk HPV. Clinical and pathological data, including tumor stage and demographic variables, were analyzed.

Results: Overall HPV prevalence was 90.1%. Site-specific positivity was highest in cervical cancers (95.8%) and vulvovaginal cancers (100%), followed by oral (84.2%) and oropharyngeal (66.7%) cancers. HPV16 and HPV31 were the dominant genotypes across all tumor sites, whereas HPV18 and HPV45 were detected at lower frequencies. Cervical cancer cases predominantly presented in advanced stages (FIGO IIB–IIIB), while vulvovaginal cancers were diagnosed at earlier stages.

Conclusion: HPV infection, particularly with HPV16/31, is highly prevalent in multiple anogenital and head and neck squamous cell carcinomas in this Indian cohort. These findings reinforce the importance of HPV vaccination programs, highlight the need for comprehensive HPV screening strategies, and suggest that P16 immunohistochemistry (IHC) should be integrated with PCR-based detection to establish oncogenic causality.

[1] Warowicka A, Nawrot R, Broniarczyk J, Węglewska M, Goździcka-Józefiak A. Oncogenic viruses and cancer. Postepy Biochem 2020; 66(4): 336-55.

[2] Soheili M, Keyvani H, Soheili M, Nasseri S. Human papilloma virus: A review study of epidemiology, carcinogenesis, diagnostic methods, and treatment of all HPV-related cancers. Med J Islam Repub Iran 2021; 35: 65.

[3] Hathaway JK. HPV: diagnosis, prevention, and treatment. Clin Obstet Gynecol 2012; 55(3): 671-80.

[4] Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14(2): 467-75.

[5] Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020; 8(2): e191-203.

[6] de Sanjosé S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11(11): 1048-56.

[7] de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017; 141(4): 664-70.

[8] Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol 2015; 33(29): 3235-42.

[9] Isayeva T, Li Y, Maswahu D, Brandwein-Gensler M. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 2012; 6(Suppl 1): S104-20.

[10] Lewis JS Jr, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med 2018; 142(5): 559-97.

[11] Westra WH. The changing face of head and neck cancer in the 21st century: the impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol 2014; 8(1): 11-20.

[12] O’Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012; 48(12): 1191-201.

[13] Chaturvedi AK, Graubard BI, Broutian T, Pickard RKL, Tong ZY, Xiao W, et al. Effect of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the United States. J Clin Oncol 2018; 36(26): 2629-37.

[14] Basu P, Malvi SG, Joshi S, Bhatla N, Muwonge R, Lucas E, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after vaccination in women in India: a multicentre, cluster-randomised trial. Lancet Infect Dis 2021; 21(11): 1448-56.

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.